Climb Bio, formerly Eliem Therapeutics, files SEC material-event reports that document financial results and public-company disclosures following its transition to an immunology-focused biotechnology business. The company’s 8-K reporting includes furnished quarterly results, operating updates and related exhibit disclosures.
Regulatory filings for this issuer also frame capital-structure, governance, shareholder-voting and clinical or regulatory disclosure categories tied to its development-stage pipeline and corporate status as a renamed Nasdaq biotechnology company.
Climb Bio, Inc. reported a net loss of $8.7 million for Q2 2025 and $29.4 million for the six months ended June 30, 2025. The company held $22.7 million in cash and $164.0 million in marketable securities (short- and long-term combined), giving available cash, cash equivalents and marketable securities of approximately $187.4 million as of June 30, 2025. Climb Bio had 67.8 million shares outstanding.
The period reflected increased research and development spending related to budoprutug and the CLYM116 license, including a $9.0 million upfront payment under the Mabworks agreement and higher clinical start-up and manufacturing costs for budoprutug after the Tenet acquisition. The company recorded prior acquired IPR&D expense of $51.7 million tied to the June 2024 Tenet acquisition. Management states current resources are expected to fund operations through 2027.
Climb Bio, Inc. announced it furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the company states the information is being furnished and not filed for purposes of Section 18 of the Exchange Act, meaning it is provided to investors but not incorporated into other filings by reference.
The company’s common stock trades on The Nasdaq Stock Market under the ticker CLYM. The report is signed on behalf of the registrant by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer. Financial details themselves are contained in the attached press release.
Thomas Stephen Basil, a director of Climb Bio, Inc. (CLYM), had restricted stock units granted on June 27, 2024 vest after performance milestones were deemed achieved on 08/07/2025, resulting in the acquisition of 100,375 shares of common stock. The award was settled at a $0 per-share price as reported.
Following the vesting event, Mr. Basil's direct beneficial ownership increased to 304,657 shares. The Form 4 discloses that the RSUs were subject to performance-based milestones and continuous service and that the milestones were deemed achieved, causing full vesting of the award.